Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXCL501 in Agitation Associated With Bipolar Disorder
NCT04276883Phase 3Completed
- Sponsor
- BioXcel Therapeutics, Inc.
- Start
- Feb 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dexmedetomidine in agitation, sponsored by BioXcel Therapeutics, Inc.. Started Feb 2020; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
agitation
Beyond the preview
Go deeper on NCT04276883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04276883.